Compound class:
Synthetic organic
Comment: SX682 is a selective and reversible antagonist (negative allosteric modulator) of the C-X-C motif chemokine receptors CXCR1 and CXCR2. It is orally bioavailable and is being investigated for potential anti-inflammatory and antineoplastic activities. It was developed by Syntrix Pharmaceuticals. The chemical structure presented here was obtained from the NIH's NCI drug Dictionary
|
|
Immunopharmacology Comments |
SX682 is an orally bioavailable, selective and reversible negative allosteric modulator of the chemokine receptors for IL-8 (CXCL8), CXCR1 and CXCR2. It is being investigated principally as an antineoplastic immuno-oncology agent. SX682 inhibits the activation of CXCR1/2 by tumour-secreted chemokines, thus reducing the recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils to the tumour microenvironment (TME), which liberates effector cells (natural killer cells and cytotoxic T lymphocytes) to eliminate cancer cells. |